Study suggests persons who recover from COVID-19 may need one vaccine dose
On
By Sola Ogundipe
Those who have had COVID-19 may only need one vaccine dose, a new study suggests People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but a little immune benefit after the second dose, according to new research from the Penn Institute of Immunology.
The findings, published in Science Immunology, suggest only a single vaccine dose may be needed to produce a sufficient antibody response.
The team found that those who did not have COVID-19 called COVID naïve did not have a full immune response until after receiving their second vaccine dose, reinforcing the importance of completing the two recommended doses for achieving strong levels of immunity.
E-Mail
PHILADELPHIA Piperlongumine, a chemical compound found in the Indian Long Pepper plant (Piper longum), is known to kill cancerous cells in many tumor types, including brain tumors. Now an international team including researchers from the Perelman School of Medicine at the University of Pennsylvania has illuminated one way in which the piperlongumine works in animal models and has confirmed its strong activity against glioblastoma, one of the least treatable types of brain cancer.
The researchers, whose findings were published this month in
ACS Central Science, showed in detail how piperlongumine binds to and hinders the activity of a protein called TRPV2, which is overexpressed in glioblastoma in a way that appears to drive cancer progression. The scientists found that piperlongumine treatment radically shrank glioblastoma tumors and extended life in two mouse models of this cancer, and also selectively destroyed glioblastoma cells taken from human patients.
New Publications Highlight Clinical Benefits of Avinger PAD Therapies theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Avinger, Inc.: New Publications Highlight Clinical Benefits of Avinger PAD Therapies
REDWOOD CITY, CA / ACCESSWIRE / April 21, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the publication of two clinical studies in peer-reviewed journals, further supporting the clinical benefits of its therapeutic devices. The studies were based on separate clinical case series conducted by physicians at the Division of Cardiovascular Disease and Endovascular Medicine at the Einstein Medical Center in Philadelphia, Pennsylvania. These two studies demonstrate the utility of Avinger s OCT-guided approach for the treatment of PAD in complex and challenging cases and patient populations, commented Dr. Jon George, an interventional cardiologist and endovascular specialist at the University of Pennsylvania Health
Penn study finds that people who recovered from COVID-19 may only need one dose of the vaccine thedp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedp.com Daily Mail and Mail on Sunday newspapers.